Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Compression Therapy for Leg Ulcers and Kaposi Sarcoma in Western Kenya

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03404297
Recruitment Status : Recruiting
First Posted : January 19, 2018
Last Update Posted : April 12, 2018
Sponsor:
Collaborators:
University of California, San Francisco
Moi Teaching and Referral Hospital
Moi Univeristy
Purdue University
Indiana Clinical and Translational Sciences Institute
Information provided by (Responsible Party):
Indiana University

Brief Summary:
The efficacy of locally sourced compression therapy in the management of chronic leg ulcers and Kaposi Sarcoma in western Kenya will be studied in a rural setting

Condition or disease Intervention/treatment Phase
Chronic Leg Ulcer Kaposi Sarcoma HIV/AIDS and Infections Other: Locally sourced compression therapy Not Applicable

Detailed Description:
Compression therapy is a well-established cornerstone therapy and part of routine clinical care for chronic leg ulcers from venous disease and lymphedema, including Kaposi sarcoma (KS)-associated lymphedema. Chronic leg ulcers, from trauma or chronic venous disease, and lymphedema have a significant impact on quality of life, driven by pain, foul odor, and restricted mobility. The provision of compression therapy in resource-limited settings, as in western Kenya and other regions of East Africa, is a major challenge. In western Kenya, locally available elastic stockings are priced at 10-15 USD (1000-1500 kshs) per pair. Pre-packaged brand name kits are not locally available or affordable for patients, as imported kits costs 7-20 USD (700-2000 kshs) per package. However, materials used routinely in wound care, namely elastic crepe, gauze, and zinc oxide, are readily available and affordable for patients. Supplies required to dress one affected leg for a week cost 2 USD (200 kshs). The use of locally-sourced routine wound care supplies for compression therapy is poised to have significant impact on reducing morbidity, social stigma, and economic loss associated with chronic leg ulcers and Kaposi sarcoma-associated lymphedema. Demonstration of its feasibility and efficacy in treating chronic leg ulcers and Kaposi sarcoma-associated lymphedema in western Kenya could have far-reaching implications for the treatment of these prevalent conditions across East Africa and sub-Saharan Africa. This project will utilize a 1) retrospective study design to evaluate the efficacy of compression therapy for the treatment of chronic leg ulcer patients seen at Turbo Health Center, one of the Academic Model for Providing Access to Healthcare (AMPATH) sites and 2) randomized controlled trial to evaluate the efficacy of compression therapy in the management of Kaposi sarcoma leg lymphedema patients seen at AMPATH/MTRH oncology clinics. If the outcomes of this project support the use of locally-sourced compression therapy in the treatment of chronic leg ulcers and Kaposi sarcoma-associated lymphedema, future studies for chronic leg ulcers will focus on scaling up use of locally-sourced compression therapy at other AMPATH clinics and exploring feasibility of community-based care. Future studies for Kaposi sarcoma lymphedema will focus on exploring feasibility of community or home-based lymphedema care.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 250 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

The study will include two different types of evaluation based on the disease process that the patient has. For patients with chronic leg ulcers, a retrospective, observational approach will be used to track the efficacy of locally sourced compression in improving wound healing.

For patients with Kaposi Sarcoma associated leg lymphedema, they will be randomized to to receive immediate compression therapy or delayed compression therapy.

Masking: None (Open Label)
Masking Description: The trial is open label but the randomization scheme will be determined by an automatic randomization algorithm performed independently of the investigators
Primary Purpose: Treatment
Official Title: Evaluation of Locally-sourced Compression Therapy for Treatment of Chronic Leg Ulcers and Management of Kaposi Sarcoma Leg Lymphedema in Western Kenya
Actual Study Start Date : March 1, 2018
Estimated Primary Completion Date : December 31, 2019
Estimated Study Completion Date : June 15, 2020


Arm Intervention/treatment
Experimental: Immediate Compression Therapy Arm
Patients in this arm will receive a locally sourced version of compression therapy while concurrently receiving chemotherapy
Other: Locally sourced compression therapy
The dressing is made up of a zinc oxide impregnated compression wrapping

Placebo Comparator: Delayed Compression Therapy Arm
Patients in this arm will receive a locally sourced version of compression therapy after completing ~ 14 weeks of chemotherapy.
Other: Locally sourced compression therapy
The dressing is made up of a zinc oxide impregnated compression wrapping




Primary Outcome Measures :
  1. Complete Resolution of ulcers (Chronic Leg Ulcer Evaluation) [ Time Frame: 3 years ]
    Proportion of completely healed ulcers at 12 weeks. The unit is number of patients with an ulcer, not number of ulcers.

  2. Change in Lower Extremity Lymphedema Index (LELI) for KS [ Time Frame: 3 years ]
    The Lower Extremity Lymphedema Index (LELI) is calculated by taking the sum of the squares of the circumference in 5 areas of a lower extremity and dividing it by the BMI. The LEL indices are significantly correlated with clinical stages and can be used as a severity scale. The LELI will compared at numerous time points throughout the study with the change in week 0 and week 14 being compared between the two arms.


Secondary Outcome Measures :
  1. Time elapsed between start of wound care and complete healing of wound (Chronic Leg Ulcer Evaluation) [ Time Frame: 3 years ]
    This will be assessed for the observational assessment of chronic leg ulcers

  2. Pain and itch assessment using the Numerical Rating Scale (Chronic Leg Ulcer Evaluation) [ Time Frame: 3 years ]
    Changes in the Numerical Rating Scale will be Evaluated over the period of evaluation. This marker has been previously validated in the Kenyan setting we work in.

  3. Ability to work (Chronic Leg Ulcer Evaluation) [ Time Frame: 3 years ]
    The time to improvement that facilitates work will be evaluated over the course of the observational assessment

  4. Ability to perform household tasks (Chronic Leg Ulcer Evaluation) [ Time Frame: 3 years ]
    The time to improvement that facilitates completion of household duties will be evaluated over the course of the observational assessment

  5. Lymphedema Quality-of-Life measure (LYMQOL) for Kaposi Sarcoma [ Time Frame: 3 years ]
    The Lymphedema Quality-of-Life measure (LYMQOL) has separate tools for assessing arm lymphedema and leg lymphedema. This will be compared across the two arms of the study

  6. Change in EORTC in Kaposi Sarcoma [ Time Frame: 3 years ]
    The change in the EORTC QLQ C30 (overall health quality of life in cancer patients) will be used to compare changes from Week 0 to Week 14 between immediate intervention and delayed arm. The EORTC QLQ-C30 is a questionnaire developed by the European Organization for Research and Treatment of Cancer to assess the quality of life of cancer patients



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Retrospective Chronic Leg Ulcer Arm Investigation

Inclusion Criteria:

  • Older than 18 years of age
  • Received paste bandage compression therapy as part of routine wound care
  • Presence of venous ulcer for more than 6 weeks. Venous ulcer defined as a wound of the lower extremity in an individual with adequate lower extremity arterial flow located in the gaiter region of the leg (between the knee and ankle) with clinical signs of venous disease (edema, varicose veins) (19) OR
  • Presence of trauma-related ulcer for more than 6 weeks

Exclusion Criteria:

  • Patients with peripheral arterial disease as documented via documented history or peripheral vascular physical examination. (20)
  • Patients diagnosed with diabetic foot ulcers
  • Patients diagnosed with ulcers from inflammatory conditions (pyoderma gangrenosum, vasculitis, rheumatoid arthritis, and other connective tissue diseases/autoimmune diseases)
  • Concomitant diagnosis of decompensated heart failure, acute phase dermatitis (at the time of the study), acute phase deep vein thrombosis

Prospective Kaposi Sarcoma Investigation

Inclusion Criteria:

  • Older than 18 years of age
  • Diagnosis of biopsy-proven Kaposi sarcoma with associated leg lymphedema
  • Leg lymphedema consistent with Campisi Clinical Stage 1B, 2, 3, 4 (Table 4). At these stages, lymphedema is clinically evident and not yet permanently fibrotic, sclerotic, or indurated with verrucous change.
  • HIV positive
  • On highly active anti-retroviral therapy
  • About to initiate a course of chemotherapy
  • Willingness to participate for the entire study duration, ranging from at least 14 weeks and up to 24 weeks, depending on randomization.
  • Provision of written Informed Consent

Exclusion Criteria

  • HIV negative
  • Leg lymphedema consistent with Campisi Clinical Stage 1A or 5 (Table 4). At these stages, lymphatic dysfunction is not yet clinically evident (Stage 1A) or lymphedema has become permanently fibrotic, sclerotic, or indurated with verrucous change (Stage 5).
  • History of another cancer diagnosis
  • Concomitant peripheral arterial disease as documented via history or peripheral vascular physical examination
  • Concomitant diagnosis of decompensated heart failure, acute phase dermatitis (at the time of the study), rheumatoid arthritis, acute phase deep vein thrombosis
  • Diagnosis of medical conditions that may also lead to lower extremity lymphedema, including: congestive heart failure, filiariasis, previous vein stripping or peripheral vascular surgery
  • Current use of medications known to cause edema, (i.e. calcium channel blockers, systemic corticosteroids)
  • Pregnant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03404297


Contacts
Layout table for location contacts
Contact: Sonak D Pastakia, PharmD,PhD 2155949414 spastaki@gmail.com
Contact: Rakhi Karwa, PharmD +1 (415) 572-3621 rakhikarwa@gmail.com

Locations
Layout table for location information
Kenya
Chulaimbo District Hospital Recruiting
Chulaimbo, Nyanza, Kenya
Contact: Edith Chepngeno, BPharm       edithtonui@gmail.com   
Moi Teaching and Referral Hospital Recruiting
Eldoret, Uasin Gishu, Kenya, 30100
Contact: Sonak Pastakia       spastaki@gmail.com   
Sponsors and Collaborators
Indiana University
University of California, San Francisco
Moi Teaching and Referral Hospital
Moi Univeristy
Purdue University
Indiana Clinical and Translational Sciences Institute
Investigators
Layout table for investigator information
Principal Investigator: Sonak D Pastakia, PharmD,PhD Purdue University

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Indiana University
ClinicalTrials.gov Identifier: NCT03404297     History of Changes
Other Study ID Numbers: 1710769547
First Posted: January 19, 2018    Key Record Dates
Last Update Posted: April 12, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: We don't intend to share this information unless there is a compelling, patient centered reason for sharing this information.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Indiana University:
compression therapy
Kenya
Kaposi Sarcoma
Locally sourced
wrapping
chronic leg ulcers
Additional relevant MeSH terms:
Layout table for MeSH terms
Sarcoma, Kaposi
Sarcoma
Leg Ulcer
Skin Ulcer
Ulcer
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Pathologic Processes
Skin Diseases
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Neoplasms, Vascular Tissue